{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"}],"units":"Participants"}],"description":"To continue to determine the safety and tolerability of DFMO as a single agent and in pediatric and young adult patients with high risk neuroblastoma that is in remission.","groups":[{"description":"Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.\n\nDFMO: Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.","id":"OG000","title":"DFMO Twice Daily"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Stratum 1 and 2 were analyzed together as one safety group as per statistical analysis plan.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","type":"SECONDARY","unitOfMeasure":"Participants"}